Javier Ángel Aristizábal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Javier Ángel Aristizábal has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Duarte
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
4 shared publications - Raúl Alexis Suarez Rodríguez
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
4 shared publications - Ricardo Sánchez
Instituto de Investigaciones Clínicas, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia
4 shared publications - Sandra Esperanza Diaz Casas
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
4 shared publications - Iván Fernando Mariño Lozano
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
3 shared publications - Mauricio García-Mora
Functional Unit for Breast and Soft Tissue Tumors, Instituto Nacional de Cancerología, Bogotá 111511, Colombia
3 shared publications
Latest Publications
- Open Access
Oncologic Outcomes of Breast-Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast-conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with non-metastatic breast cancer at a referral cancer center in a medium-resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as the initial treatment and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow-up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were a locally advanced clinical stage (HR 5.13; p = 0.01), triple-negative subtype (HR 8.02; p < 0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p < 0.01). Conclusions: Breast-conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. The time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
Open AccessOncologic Outcomes of Breast-Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast-conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with non-metastatic breast cancer at a referral cancer center in a medium-resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as the initial treatment and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow-up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were a locally advanced clinical stage (HR 5.13; p = 0.01), triple-negative subtype (HR 8.02; p < 0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p < 0.01). Conclusions: Breast-conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. The time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
- Open Access
- 7 February 2025
- Published by MDPI AG in Preprints.org
Oncologic Outcomes of Breast‐Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast‐conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with nonmetastatic breast cancer at a referral cancer center in a medium‐resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as initial treatment, and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow‐up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were locally advanced clinical stage (HR 5.13; p =0.01), triple‐negative subtype (HR 8.02; p <0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p <0.01). Conclusions: Breast‐conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. Time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
- 7 February 2025
- Published by MDPI AG in Preprints.org
Open AccessOncologic Outcomes of Breast‐Conserving Surgery in a Colombian Cancer Center: An Observational, Analytical, Retrospective Cohort Study
Background: Breast‐conserving surgery (BCS) is one of the major surgical advances in breast cancer treatment. This study evaluated the oncological outcomes of BCS in patients with nonmetastatic breast cancer at a referral cancer center in a medium‐resource country between 2013 and 2019. Methods: An observational, analytical, retrospective cohort study was conducted on patients with stage I–IIIC breast cancer treated at the Instituto Nacional de Cancerología (Bogotá, Colombia) from September 2013 to March 2019. Demographic data, tumor characteristics, treatment types, and survival outcomes were retrospectively collected. Results: A total of 409 patients were included. In 64.1% of cases, BCS was performed as initial treatment, and in 35.9%, after neoadjuvant chemotherapy (NACT). With a median follow‐up of 85.2 months, tumor recurrence was documented in 9.04% of patients, local recurrence in 2.9%, regional in 2.2%, and distant in 5.6%. The identified risk factors for mortality were locally advanced clinical stage (HR 5.13; p =0.01), triple‐negative subtype (HR 8.02; p <0.01), and nodal involvement of more than four lymph nodes in the surgical specimen (HR 4.00; p <0.01). Conclusions: Breast‐conserving surgery is an oncologically safe procedure for patients with early and locally advanced breast cancer who respond to NACT. Time to recurrence and overall survival are determined by the clinical stage, axillary tumor burden, and biological subtype of the disease.
- Open Access
- 26 March 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (4) , 1725-1738
Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center
Introduction: Soft tissue sarcomas (STS) are low-incidence tumors whose clinical and histopathological factors are associated with adverse oncological outcomes. This study evaluated prognostic factors (PF) associated with tumor recurrence and overall survival (OS) in patients diagnosed with STS of the extremities, treated at the Instituto Nacional de Cancerología (INC), Bogotá, Colombia. Materials and Methods: An analytical observational study of a historical cohort was carried out, including patients diagnosed with STS and managed surgically in the Functional Unit for Breast and Soft Tissue Tumors of the INC from January 2008 to December 2018. Results: A total of 227 patients were included; 74.5% had tumors greater than 5 cm. Most patients (29.1%) were in stage IIIB at diagnosis. Age was associated with higher mortality (HR = 1.01; CI95%: 1–1.02; p = 0.048). Tumor persistence at admission to the INC (HR = 2.34; CI95%: 1.25–4.35; p = 0.007) and histologic grade III (HR = 5.36; CI95%: 2.29–12.56; p = p = 0.014 and HR = 6.09; CI95%: 2.03–18.2; p = 0.001), respectively. Tumor size (HR = 1.03; CI95%: 1–1.06; p = 0.015) and histologic grade III (HR = 4.53; CI95%: 1.42–14.49; p = 0.011) were associated with a higher risk of distant recurrence. Conclusions: This cohort showed that in addition to histologic grade and tumor size, tumor persistence at the time of admission has an impact on disease recurrence, so STS should be managed by a multidisciplinary team with experience in this pathology in high-volume reference centers.
- 26 March 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (4) , 1725-1738
Open AccessPrognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center
Introduction: Soft tissue sarcomas (STS) are low-incidence tumors whose clinical and histopathological factors are associated with adverse oncological outcomes. This study evaluated prognostic factors (PF) associated with tumor recurrence and overall survival (OS) in patients diagnosed with STS of the extremities, treated at the Instituto Nacional de Cancerología (INC), Bogotá, Colombia. Materials and Methods: An analytical observational study of a historical cohort was carried out, including patients diagnosed with STS and managed surgically in the Functional Unit for Breast and Soft Tissue Tumors of the INC from January 2008 to December 2018. Results: A total of 227 patients were included; 74.5% had tumors greater than 5 cm. Most patients (29.1%) were in stage IIIB at diagnosis. Age was associated with higher mortality (HR = 1.01; CI95%: 1–1.02; p = 0.048). Tumor persistence at admission to the INC (HR = 2.34; CI95%: 1.25–4.35; p = 0.007) and histologic grade III (HR = 5.36; CI95%: 2.29–12.56; p = p = 0.014 and HR = 6.09; CI95%: 2.03–18.2; p = 0.001), respectively. Tumor size (HR = 1.03; CI95%: 1–1.06; p = 0.015) and histologic grade III (HR = 4.53; CI95%: 1.42–14.49; p = 0.011) were associated with a higher risk of distant recurrence. Conclusions: This cohort showed that in addition to histologic grade and tumor size, tumor persistence at the time of admission has an impact on disease recurrence, so STS should be managed by a multidisciplinary team with experience in this pathology in high-volume reference centers.
- Open Access
- 22 January 2024
- Published by MDPI AG in Preprints.org
Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center
Introduction: Soft tissue sarcomas (STS) are low-incidence tumors whose clinical and histopathological factors are associated with adverse oncological outcomes. This study evaluated prognostic factors (PF) associated with tumor recurrence and overall survival (OS) in patients diagnosed with STS of the extremities, treated at the Instituto Nacional de Cancerología (INC), Bogotá, Colombia. Materials and methods: An analytical observational study of a historical cohort was carried out, including patients diagnosed with STS and managed surgically in the Functional Unit for Breast and Soft Tissue Tumors of the INC from January 2008 to December 2018. Results: A total of 227 patients were included; 74.5% had tumors greater than 5 cm. Most patients (29.1%) were in stage IIIB at diagnosis. Age was associated with higher mortality (HR=1.01; CI95%: 1–1.02; p=0.048); tumor persistence at admission to the INC (HR=2.34; CI95%: 1.25–4.35; p=0.007), and histologic grade III (HR=5.36; CI95%: 2.29–12.56; p=<0.001) showed statistical significance in the multivariate analysis for recurrence of any type, as were the PFs associated with a higher risk of local recurrence (HR=2.85; CI95%: 1.23–6.57; p=0.014 and HR=6.09; CI95%: 2.03–18.2; p=0.001), respectively. Tumor size (HR=1.03; CI95%: 1–1.06; p=0.015) and histologic grade III (HR=4.53; CI95%: 1.42–14.49; p=0.011) were associated with a higher risk of distant recurrence. Conclusion: This cohort showed that in addition to histologic grade and tumor size, tumor persistence at the time of admission has an impact on disease recurrence, so STS should be managed by a multidisciplinary team with experience in this pathology in high-volume reference centers.
- 22 January 2024
- Published by MDPI AG in Preprints.org
Open AccessPrognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference Cancer Center
Introduction: Soft tissue sarcomas (STS) are low-incidence tumors whose clinical and histopathological factors are associated with adverse oncological outcomes. This study evaluated prognostic factors (PF) associated with tumor recurrence and overall survival (OS) in patients diagnosed with STS of the extremities, treated at the Instituto Nacional de Cancerología (INC), Bogotá, Colombia. Materials and methods: An analytical observational study of a historical cohort was carried out, including patients diagnosed with STS and managed surgically in the Functional Unit for Breast and Soft Tissue Tumors of the INC from January 2008 to December 2018. Results: A total of 227 patients were included; 74.5% had tumors greater than 5 cm. Most patients (29.1%) were in stage IIIB at diagnosis. Age was associated with higher mortality (HR=1.01; CI95%: 1–1.02; p=0.048); tumor persistence at admission to the INC (HR=2.34; CI95%: 1.25–4.35; p=0.007), and histologic grade III (HR=5.36; CI95%: 2.29–12.56; p=<0.001) showed statistical significance in the multivariate analysis for recurrence of any type, as were the PFs associated with a higher risk of local recurrence (HR=2.85; CI95%: 1.23–6.57; p=0.014 and HR=6.09; CI95%: 2.03–18.2; p=0.001), respectively. Tumor size (HR=1.03; CI95%: 1–1.06; p=0.015) and histologic grade III (HR=4.53; CI95%: 1.42–14.49; p=0.011) were associated with a higher risk of distant recurrence. Conclusion: This cohort showed that in addition to histologic grade and tumor size, tumor persistence at the time of admission has an impact on disease recurrence, so STS should be managed by a multidisciplinary team with experience in this pathology in high-volume reference centers.